The user documented eight weeks of progress using 5% topical minoxidil, 1 mg oral finasteride, and weekly microneedling. They reported diffuse fill-in and new baby hairs, with plans to taper off topical minoxidil.
Microneedling daily at 0.3mm combined with topical finasteride and minoxidil is effective for hair thickening, with added benefits from near-infrared therapy. The approach may not improve the front hairline, and deeper microneedling is done monthly for better results.
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.
Koshine 826 (Pyrilutamide) has mixed reviews, with some users experiencing side effects like insomnia and others seeing minimal results. Concerns about the company's transparency and lack of progress photos are noted.
The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.
Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.
The user experienced initial success with topical finasteride 0.025% and melatonin but noticed rapid hair thinning after three months. They are considering switching to a higher dose of topical finasteride or oral finasteride, as advised by others, while being cautious about potential side effects.
The conversation discusses hair regrowth treatments, including stem cell exosomes, PRP, and PP405. Users question the effectiveness of the treatments and mention finasteride and minoxidil.
GHK-Cu is discussed for its potential anti-aging and healing properties, with some users considering its effects on hair growth. One user mentions using Folligen Spray and topical finasteride, noting improved healing but uncertain hair growth results.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
KX-826 shows promise for hair maintenance at higher doses with minimal side effects, despite failing Phase III trials. The user believes it is more effective than Minoxidil, Finasteride, and RU58841.
A user is experiencing facial bloating from low-dose topical finasteride due to high estradiol levels and is seeking advice on using DIM to manage this issue, including dosage and brand recommendations.
The conversation is about whether finasteride can be mixed with just water for a topical solution and if Isopropyl Alcohol and Propylene Glycol are necessary for effectiveness and faster drying. The user is seeking advice on the formulation of topical finasteride.
A user's father experienced hair regrowth and other health improvements after two IV exosome treatments. The user also had four rounds of exosome therapy, noting significant hair regrowth and relief from headaches, but no change in gray hair.
A 7-month progress report of using finasteride and minoxidil, as well as keto dieting and derma stamping; the discussion also touched on RU58841 and its potential side effects.
The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.
A user has been taking finasteride for 7 months and is experiencing watery semen as the only side effect. They are considering taking zinc supplements to improve this condition.
After six months of using a 0.50mm derma roller, 5% minoxidil, and a 5000 mcg biotin supplement, the user saw hair improvement. They are considering alternatives to finasteride due to concerns about side effects.
The user resumed using topical finasteride after a two-week break and will update on side effects like water retention and gynecomastia in a month. They are also starting DIM and zinc.
The conversation is about using Xeljanz for hair regrowth in individuals with LPP. The user is seeking experiences and expectations from others who have tried this treatment.
A user shared their 88-day progress using 1.25mg finasteride, topical minoxidil, and weekly 1mm microneedling, noting improvement from NW 4.5 to around NW 3. Another user complimented the progress.
The conversation discusses creating a topical catalase solution with phosphate buffered saline, glycerin, and polysorbate 20 for hair loss treatment. The user seeks advice on preparing this solution.
New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.
The conversation discusses Scube3, a seemingly new and obscure treatment for hair loss, with limited information available and a link to a patient intake form.
A 26-year-old male experienced hair regrowth and increased density after 6 months using oral finasteride and minoxidil tablets, along with a derma pen, multivitamins, omega-3, creatine, and L-citrulline. He plans to add RU58841 soon and is hopeful for further improvement.
The user is experiencing hair loss after a hair transplant and is considering using fluridil (Eucapil) and possibly alfatradiol as treatments, as they couldn't tolerate finasteride or minoxidil. The manufacturer of Eucapil confirmed they won't produce higher concentrations due to lack of efficacy.
A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.